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Clinics and pathology 
Disease 
Acute myeloid leukaemia (AML) 
Phenotype / cell stem origin 
One de novo AML (M2 type), and a therapy related 
AML (t-AML). 
Epidemiology 
The de novo AML was a 11 year old girl; the t-AML 
case was a 58 year old female patient who had been 
treated for ovary carcinoma with melphalan 1.5 years 
before. 
Prognosis 
No complete remission (CR) in the de novo case; CR 
was obtained but a relapse occurred and the patient 








Sole anomaly in the de novo AML case; complex 
karyotype in the t-AML case, with -5 and other 
abnormalities. 
Genes involved and Proteins 
Note: Genes involved are unknown. 
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